FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packageus.nlm.vsac
Resource TypeValueSet
IdValueSet-2.16.840.1.113762.1.4.1078.1340.json
FHIR VersionR4
Sourcehttps://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1078.1340/expansion
URLhttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1340
Version20250911
Statusactive
Date2025-09-11T01:02:40-04:00
NameDualEndothelinReceptorAntagonist
TitleDual Endothelin Receptor Antagonist
Realmus
Authorityhl7
Purpose(Clinical Focus: Medications that are dual endothelin receptor antagonists (Aprocitentan)),(Data Element Scope: RxCUI),(Inclusion Criteria: Prescribable drugs),(Exclusion Criteria: N/A)

Resources that use this resource

No resources found


Resources that this resource uses

CodeSystem
rxnormRxNorm

Narrative

No narrative content found in resource


Source1

{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1078.1340",
  "meta": {
    "versionId": "5",
    "lastUpdated": "2025-09-11T01:02:40.000-04:00",
    "profile": [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueContactDetail": {
        "name": "Optum Author"
      }
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate": "2025-09-11"
    },
    {
      "url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate": "2025-09-11"
    }
  ],
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1340",
  "identifier": [
    {
      "system": "urn:ietf:rfc:3986",
      "value": "urn:oid:2.16.840.1.113762.1.4.1078.1340"
    }
  ],
  "version": "20250911",
  "name": "DualEndothelinReceptorAntagonist",
  "title": "Dual Endothelin Receptor Antagonist",
  "status": "active",
  "date": "2025-09-11T01:02:40-04:00",
  "publisher": "Optum Steward",
  "jurisdiction": [
    {
      "coding": [
        {
          "system": "urn:iso:std:iso:3166",
          "code": "US"
        }
      ]
    }
  ],
  "purpose": "(Clinical Focus: Medications that are dual endothelin receptor antagonists (Aprocitentan)),(Data Element Scope: RxCUI),(Inclusion Criteria: Prescribable drugs),(Exclusion Criteria: N/A)",
  "compose": {
    "include": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "concept": [
          {
            "code": "2679064",
            "display": "aprocitentan 12.5 MG Oral Tablet"
          },
          {
            "code": "2679070",
            "display": "aprocitentan 12.5 MG Oral Tablet [Tryvio]"
          }
        ]
      }
    ]
  },
  "expansion": {
    "identifier": "urn:uuid:3702d82a-9452-4656-b572-2b68db655584",
    "timestamp": "2025-11-24T11:44:03-05:00",
    "total": 2,
    "contains": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "09022025",
        "code": "2679064",
        "display": "aprocitentan 12.5 MG Oral Tablet"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "09022025",
        "code": "2679070",
        "display": "aprocitentan 12.5 MG Oral Tablet [Tryvio]"
      }
    ]
  }
}